THETFORD MINES, QC, May 21, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to ...

MYCN and MDM2 inhibition has gained attention not only in neuroblastoma but also in a spectrum of other cancer types due to their potential in targeting key oncogenic pathways.

MYCN and MDM2 inhibition has gained attention not only in neuroblastoma but also in a spectrum of other cancer types due to their potential in targeting key oncogenic pathways.

MYCN and MDM2 inhibition has gained attention not only in neuroblastoma but also in a spectrum of other cancer types due to their potential in targeting key oncogenic pathways.

Speaking at a ribbon-cutting ceremony on 20 June, KDA president Eirik Lie said the Nexus plant would significantly increase production capacity for both the Naval Strike Missile (NSM) and the air ...

KDA vice-chairman Vishak G Iyer takes steps to execute the schemes. Rs 41.50 crore allotted for internal roads, Rs 70 crore for STP construction in New Kanpur City scheme, and Rs 5.78 crore for ...

Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML) MDM2 degraders shown ...

Kymera claims that KT-253 is able to avoid an increase in MDM2 and kill cancer cells, even with brief exposures. As a result, it is being explored for AML, as well as a variety of other liquid and ...

KARACHI: A "grand operation" by the Karachi Development Authority (KDA) to retrieve illegally occupied state land in Gulistan-e-Jauhar was called off on Tuesday after strong resistance from squatters.

MDM2 amplification occurs in 3.5% to 7.0% of human cancers, although no specific copy-number threshold for the alteration has been determined. In DDLPS, intimal sarcomas, and certain other tumors ...

The MDM2–p53 antagonist BI 907828 has shown preclinical antitumor activity in a range of malignancies and is currently being assessed in two phase Ia/Ib dose-escalation/expansion trials in patients ...

MDM2 amplification is characteristic in well-differentiated and dedifferentiated liposarcoma and is also observed in a small fraction of other solid tumors, diagnoses that may benefit from this or ...